It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).
Baxalta’s broad and diverse pipeline is built on a legacy of innovation in bleeding disorders and immunology. In addition to our core research areas of hematology, immunology, and oncology, our pipeline also includes advanced technology platforms in emerging areas such as gene therapy and biosimilars.
Serving patients is our inspiration and we are passionate about improving their lives. No matter what we do or where we work, we all strive for excellence on behalf of patients, caregivers, and healthcare providers. We seek to understand their journey. Through our insights, we will deliver breakthrough therapies and personalized services.
October 5, 2015
Baxalta and Momenta Announce Initiation of Pivotal Clinical Trial for M923, a Biosimilar Version of HUMIRA (adalimumab)
Baxalta’s culture is guided by our Values and Behaviors, which unify diverse perspectives through a dedication to opening a world of endless possibilities for the patients we serve.
Baxalta helps support patients through a variety of patient communities and additional resources. Find information and links to these resources in our Therapies section.
After decades, a correct diagnosis of primary immunodeficiency disorder is life-changing for Anthony.